drugset / Trial / NCT00505037
A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the superiority to placebo, dose-responsibility and safety.
Timeline
- Start
- 2007-10
- Primary completion
- 2008-09
- Completion
- 2008-09
Publications
- Natale P, Green SC, Ruospo M, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.
- Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kanoh H. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study. Ther Apher Dial. 2014 Jun;18 Suppl 2:24-32. doi: 10.1111/1744-9987.12202.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bixalomer | Small molecule | 1.5 g | Oral |
| Subject | Bixalomer | Small molecule | 3 g | Oral |
| Subject | Bixalomer | Small molecule | 4.5 g | Oral |
| Comparator | Sevelamer | Other / unclassified | — | Oral |